Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist
Aim:This review discusses the most common used antifungal agents in the treatment of invasive fungal infections. In addition, guidelines for the treatment of invasive aspergillosis, as used in the Ghent University Hospital, are described. Moreover, the importance of determining the effectiveness of antifungal therapy as well as the potential role of the hospital pharmacist in the management of this infection is highlighted.
Methods:A review of the English-language literature was conducted using the MEDLINE database and scientific websites. Search terms including antimycotics, antifungal therapy and invasive aspergillosis were used to refine the search, and preference was given to studies published after 1992. This was completed with recent treatment guidelines.
Results:An overview of the most recent advances in antifungal therapy is described. In addition, a flowchart for treatment of invasive aspergillosis (proven, probable or possible) has been developed.
Conclusion:Invasive fungal infections will remain a frequent and important complication of modern medicine. Considering the clinical and financial outcome of invasive fungal infections, the role of the hospital pharmacist can be a paramount to the treatment.
KeywordsAntifungal agents Aspergillosis Formulary management Guidelines Hospital pharmacist
Mossad, S 2003Prevention and treatment of fungal infections in bone marrow transplantation.Curr Hematol Rep23029PubMedGoogle Scholar
Sanglard D, Bille J. Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida
infections. In: Calderone R, editor. Washington, USA: ASM Press, 2002.
Groll, AH, Walsh, TJ 2002Antifungal chemotherapy: advances and perspectives.Swiss Med Weekly13230311Google Scholar
Prevention, diagnosis and management of invasive aspergillosis in immunocompromised patients. The Infectious Diseases Advisory Board, 2004. ISBN 90-805936-4-8.Google Scholar
Meyer, RD 1992Current role of therapy with amphotericin B.Clin Infect Dis14(Suppl.1)S154S160Google Scholar
http://www.doctorfungus.org/thedrugs/Nystatin liposomal.htm.Google Scholar
Lyman, CA, Walsh, TJ 1992Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.Drugs44935PubMedGoogle Scholar Anaissie, EJ, Kontonyiannis, DP, Huls, C, Vartivarian, SE, Karl, C, Prince, RA, Bosso, J, Bodey, GP 1995Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.J Infect Dis172599602PubMedGoogle Scholar Wheat, J, MaWhinney, S, Hafner, R, McKinsey, D, Chen, D, Korzun, A, et al. 1997National institute of allergy and infectious diseases acquired immunodeficiency syndrome clinical trials group and mycoses study group. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome.Am J Med10322332CrossRefPubMedGoogle Scholar Pappas, PG, Bradsher, RW, Kauffman, CA, Cloud, GA, Thomas, CJ, Campbell, GD, et al. 1997National institute of allergy and infectious diseases mycoses study group. Treatment of blastomycosis with higher doses of fluconazole.Clin Infect Dis25200205PubMedGoogle Scholar Vandewoude, K, Vogelaers, D, Decruyenaere, J, Jaqmin, P, De Beule, K, Peer, A, et al. 1997Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.Antimicrob Agents Chemother4127148PubMedGoogle Scholar Zhou, HH, Goldman, M, Wu, J, Woestenborghs, R, Hassell, AE, Lee, P, et al. 1998A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.J Clin Pharmacol38593602PubMedGoogle Scholar Sheehan, DJ, Hitchcock, CA, Sibley, CM 1999Current and emerging azole antifungal agents.Clin Microbiol Rev124079PubMedGoogle Scholar Law, D, Moore, CB, Denning, DW 1997Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.Antimicrob Agents Chemother41231011PubMedGoogle Scholar
Odds, FC, Brown, AJP, Gow, NAR 2003Antifungal agents: mechanisms of action.Trends Microbiol1127279CrossRefPubMedGoogle Scholar Denning, D 2002Echinocandins: a new class of antifungals.J Antimicrob Chemother4988991CrossRefPubMedGoogle Scholar Denning, D 1997Echinocandins and pneumocandins: a new antifungal class with a novel mode of action.J Antimicrob Chemoth4061114CrossRefGoogle Scholar Wiederhold, N, Lewis, R 2003The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Expert Opin Drugs12131333CrossRefGoogle Scholar Andes, D, Ogtrop, M 2000In vivo characterization of the pharmacodynamics of fIucytosine in a neutropenic murine disseminated candidiasis model.Antimicrob Agents Chemother4493842CrossRefPubMedGoogle Scholar
Wetzstein, GA 2000Intravenous to oral (IV:PO) anti-infective conversion therapy.Cancer Control71706PubMedGoogle Scholar Nathwani, D, Tillotson, G, Davey, P 1997Sequential antimicrobial therapy, the role of quinolones.J Antimicrob Chemother394416CrossRefPubMedGoogle Scholar Von Gunten , V, Amos, V, Sidler, A, Beney, J, Troillet, N, Reymond, J 2003Hospital pharmacists’ reinforcement of guidelines for switching from parenteral to oral antibiotics: a pilot study.Pharm World Sci25525CrossRefPubMedGoogle Scholar Lazarus, HM, Blumer, JL, Yanovich, S, Schlamm, H, Romero, A 2002Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.J Clin Pharmacol42395402CrossRefPubMedGoogle Scholar Laing, RB, Mackenzie, AR, Shaw, H, Gould, IM, Douglas, JG 1998The effect of intravenous-to-oral switch guidelines on the use of parenteral on use antimicrobials in medical wards.J Antimicrob Chemother4210711CrossRefPubMedGoogle Scholar Somers, A, Bauters, T, Robays, H, Bogaert, M, Colardyn, F 2002Evaluation of human albumin use in a university hospital in Belgium.Pharm World Sci241116CrossRefPubMedGoogle Scholar Nathwani, D, Gray, K, Borland, H 2002Quality indicators for antibiotic control programmes.J Hosp Infect501659CrossRefPubMedGoogle Scholar